0001562180-23-004960.txt : 20230608 0001562180-23-004960.hdr.sgml : 20230608 20230608160810 ACCESSION NUMBER: 0001562180-23-004960 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230606 FILED AS OF DATE: 20230608 DATE AS OF CHANGE: 20230608 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ZUMWALT LEANNE M CENTRAL INDEX KEY: 0001204946 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36352 FILM NUMBER: 231001963 MAIL ADDRESS: STREET 1: C/O THE ADVISORY BOARD CO WATERGATGE STREET 2: 600 NEW HAMPSHIRE AVE NW CITY: WASHINGTON STATE: DC ZIP: 20037 FORMER NAME: FORMER CONFORMED NAME: ZURNWALT LEANNE M DATE OF NAME CHANGE: 20021109 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akebia Therapeutics, Inc. CENTRAL INDEX KEY: 0001517022 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208756903 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 245 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-871-2098 MAIL ADDRESS: STREET 1: 245 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 primarydocument.xml PRIMARY DOCUMENT X0407 4 2023-06-06 false 0001517022 Akebia Therapeutics, Inc. AKBA 0001204946 ZUMWALT LEANNE M C/O AKEBIA THERAPEUTICS, INC. 245 FIRST ST. CAMBRIDGE MA 02142 true false false false false Common Stock 2023-06-06 4 A false 30000.00 0.00 A 43700.00 D Stock Option (Right to buy) 1.20 2023-06-06 4 A false 45000.00 0.00 A 2024-06-06 2033-06-06 Common Stock 45000.00 45000.00 D The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Second Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. /s / Carolyn Rucci, attorney-in-fact for LeAnne M. Zumwalt 2023-06-08